comparemela.com

Latest Breaking News On - Rhizen pharmaceuticals ag contact - Page 1 : comparemela.com

Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors

Tenalisib (RP6530, selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial

United statesFrance generalSamyukta bhagwatiKostenloser wertpapierhandelSwaroop vakkalankaRhizen pharmaceuticalsRhizen pharmaceuticals ag contactRhizen pharmaceuticals agCorporate affairs communicationsClinical benefit ratePoster presentationTamta makharadzePiotr tomczak

Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022

Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity)

Samyukta bhagwatiKostenloser wertpapierhandelSwaroop vakkalankaRhizen pharmaRhizen pharmaceuticalsRhizen pharmaceuticals ag contactRhizen pharmaceuticals agCorporate affairs communicationsCancer meetingSalt inducible kinaseTrack orphan drug designations

Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differentiated PARP inhibitor RP12146, indicates

United statesSamyukta bhagwatiKostenloser wertpapierhandelSwaroop vakkalankaRhizen pharmaAmerican association for cancer researchRhizen pharmaceuticalsRhizen pharmaceuticals ag contactRhizen pharmaceuticals agCorporate affairs communicationsRibose polymeraseDihydro orotate dehydrogenaseAmerican associationCancer researchSmall molecule therapeutic agents

vimarsana © 2020. All Rights Reserved.